PSMB8 and autoimmune disease: Immunoproteasome inhibitors have been shown to ameliorate symptoms in preclinical models of different autoimmune diseases [43, 44], and KZR-616, a drug targeting both PSMB8 and PSMB9, has been tested in a Phase II trial of systemic lupus erythematosus [45].